Biophan Technologies CEO to Speak at Wall Street Reporter Small-Cap Discovery Conference; CEO Michael Weiner to Highlight Biophan's Growth Strategies to Influential Small and Micro-Cap Equity Investors.

ROCHESTER, N.Y. -- Biophan Technologies, Inc (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that CEO Michael Weiner will present at the Wall Street Reporter's Small-Cap Discovery Conference, to be held today at the Le Parker Meridien hotel in New York, N.Y. The announcement was made by Mr. Weiner.

Mr. Weiner will address an audience comprised of Wall Street's key growth and value-oriented equity investors, managers, and analysts. Biophan Technologies is one of 15 companies selected to present at the event. Participating companies are culled from the most promising growth opportunities in various sectors, including technology, financial services, healthcare, and consumer industries. The conference is sponsored by Wall Street Reporter Magazine, a New York-based provider of financial media and publisher of the Wall Street Reporter newsletter since 1843.

Mr. Weiner will outline the market opportunities for Biophan's proprietary technologies and solutions in several multi-billion-dollar areas of the health care sector. The Company's cutting-edge nanotechnology science, in combination with other Biophan technologies, have generated a series of breakthrough opportunities in biomedicine relating to the use of Medical Resonance Imaging (MRI) for patients with implanted devices, such as pacemakers, neurostimulators, and vascular stents, for whom MRI imaging was previously either dangerous or unavailable.

"I am looking forward to showcasing the depth and breadth of the opportunities that Biophan is aggressively pursuing in some of the most dynamic and exciting areas of biomedical and nanotechnology science," Mr. Weiner said. "The markets for our solutions continue to grow on a worldwide basis, and we are making great strides in addressing the demand with our proprietary technologies and solutions."

Mr. Weiner is expected to highlight Biophan's recent product and intellectual property achievements, including the recent issuance of an array of patents with far-reaching licensing power. The Company has amassed an extensive intellectual property portfolio, and dominates several key areas of technology. It currently has 103 issued, pending, or allowed patents and boasts a proprietary research and development operation that continues to introduce ground-breaking biomedical solutions for MRI compatibility, opto-electronics, biothermal battery technology, and other areas.

"This forum is an especially appropriate place for Biophan to be present," said Mr. Weiner. "Our strategic plan is built upon the foundation of growth opportunities that optimize our science. The growth potential for Biophan's specific solutions is very substantial, and continuing the pursuit of new frontiers in biomedical use of nanotechnologies is what inspires and motivates this company."

About Wall Street Reporter

Wall Street Reporter is an online financial and investment news and information source that provides investors with first-hand information about public and private companies. Each day it interviews CEOs of leading public and select private companies to provide perspective and information to help investors make their investment decisions. For more information, visit http://www.wallstreetreporter.com.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 103 U.S. patents, licenses or applications. This total includes 25 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 70 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.